Psoriatic Arthritis

Although the incidence rates were similar among those treated with TNFi and biologics-naïve patients, patients with psoriatic arthritis had a 35% increased risk when compared with the general population.

Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.

The results imply the possibility of improving patient stratification based on both clinical and immune cellular phenotypes.

A comparative trial of biologic agents suggest IL-17A inhibitors may more significantly improve skin clearance in comorbid patients.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2022.

The results suggest a basis for clinicians to detect the earlier potential development of psoriasis, psoriatic arthritis, and Crohn’s disease.

“Respiratory tract infections constitute the most common infections in patients with rheumatic diseases, especially under immunosuppressive treatment,” investigators explained.

Identifying the current prevalence and effect of fatigue on patients with psoriatic arthritis may lead to new strategies designed to manage this commonly-reported symptom.

Holding methotrexate after the second COVID-19 vaccine dose is associated with similar immunogenicity and a lower risk of disease flare compared with withholding methotrexate after both vaccine doses.

DISCOVER-2 is a phase 3, randomized, double-blind, multicenter study assessing the safety and efficacy of subcutaneous guselkumab treatment in biologic-naïve patients with active PsA.

“The data continue to validate our hypothesis that izokibep offers differentiated efficacy with high potency and small size and reinforces izokibep’s potential to manage the hard-to-treat manifestations of PsA."

Nowell emphasized that simple changes, such as targeted walking goals and meditative breathing, are low energy and low cost, yet extremely effective.

“There's a real interest and need for wellness programs out there among people living with psoriatic arthritis. This is something that matters to them even more now living with a chronic disease.”

Deucravacitinib showed sustained efficacy in the various outcomes in psoriatic arthritis and a unique and consistent safety profile.

In this Q&A, Fabian Proft, MD, discussed the findings of his study that evaluated the DAPSA using a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis.

Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.

ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.

Low levels of disease activity were achieved and increased throughout the study.

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

Previous studies have suggested a connection between rheumatic diseases, which often affect women in their reproductive years, and adverse pregnancy outcomes, such as pre-eclampsia.

The PRERA trial was the first real-world, non-interventional study to analyze radiographic progression in patients with RA or PsA treated with etanercept.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 29, 2022.

Randomized clinical trials evaluating the effect of bDMARD or tsDMARD treatment in patients with psoriatic arthritis were included in the analysis.

Low disease activity may be the most appropriate treatment target for patients with high levels of structural damage and functional disability.

Risankizumab showed linear and time-independent pharmacokinetics in patients with active psoriatic arthritis and was comparable to those with plaque psoriasis.